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Hypertension in pregnancy is common, occurring in ≤10% of all pregnancies with ≤20% of those women hav-
ing preeclampsia. Treatment approaches of “less tight” and 
“tight” control of chronic or gestational hypertension can be 
found in international guidelines for management of hyperten-
sion in pregnancy.1
To understand the effects of these contrasting approaches, 
we undertook an open, multicenter international randomized 
controlled trial. The study is described elsewhere,2 but briefly, 
987 consenting women were enrolled between March 26, 2009 
and August 2, 2012 at centers confirmed to have capacity to pro-
vide the necessary maternal and neonatal care. Eligible women 
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were between 14 weeks 0 days and 33 weeks 6 days of gesta-
tion and had a live fetus, nonproteinuric chronic or gestational 
hypertension, an office diastolic blood pressure (BP) of 90 to 
105 mm Hg (or 85–105 mm Hg if antihypertensive medica-
tion was being taken), and had no exclusion criteria, including 
a systolic BP of ≥160 mm Hg systolic or proteinuria. Women 
were randomized to less tight BP control (target diastolic BP of 
100 mm Hg) or tight control (target diastolic BP of 85 mm Hg) 
until delivery, with labetalol as the drug of first choice. The 
primary composite outcome (pregnancy loss or high-level neo-
natal care for more than 48 hours) was similar between groups 
(adjusted odds ratio [aOR], 1.02; 95% confidence interval [CI], 
0.77–1.35). The secondary outcome of serious maternal com-
plications ≤6 weeks postpartum or until hospital discharge was 
not significantly different (aOR, 1.74; 95% CI, 0.79–3.84). 
At the prespecified 99.9% significance level for the second-
ary analysis of maternal outcomes adjusted for stratification 
factors, 40.6% of women in the less tight group experienced 
postrandomization severe hypertension compared with 27.5% 
in the tight control group (aOR, 1.80; 95% CI, 1.34–2.38). At 
the 95%, but not at the prespecified 99.9%, significance level, 
4.3% of less tight compared with 1.6% of tight women had 
thrombocytopenia (platelet count <100×109; aOR, 2.63; 95% 
CI, 1.15–6.05), and 4.3% compared with 1.8%, respectively, 
had elevated aspartate aminotransferase or alanine aminotrans-
ferase levels with symptoms (aOR, 2.33; 95% CI, 1.05–5.16), 
indicating a positive impact for women in the tight control 
group. The current analysis was planned to determine the cost 
to the healthcare system related to less tight compared with 
tight BP control of pregnancy hypertension to inform resource 
allocation decisions and policy.
Methods
Ethics approval for the trial and cost analysis was obtained from the 
trial coordinating center (University of British Columbia Clinical 
Research Ethics Board, H08-00882) and at each recruiting center. 
Informed consent was obtained from each woman before enrollment. 
The cost analysis was undertaken from the perspective of a third-
party payer (eg, Ministry of Health) as if all the study participants had 
received care in each of 3 Canadian provinces (ie, Ontario, British 
Columbia, and Alberta) to provide a sensitivity analysis of different 
price structures on the robustness of cost outcomes and to enhance 
generalizability. The study included 3 provinces that represented 63% 
(21.84 million people) of Canada’s population3 and 62.3% of total 
public sector health expenditure in Canada in 2013,4 and share similar 
provincial government-funded healthcare systems, including funding 
structures for nurses and hospitals and fee-for-service or salaries for 
physicians. Outcomes included the difference in mean cost between 
tight and less tight groups of: the total cost of 24 services in each 
province, total cost of 11 hospital ward durations, and overall total 
cost of all services and ward durations in each province. All costs 
are presented in 2013 Canadian dollars, the year that the last recruits 
delivered and study data collection ended.
Resource Use
Using case report forms for mothers and babies, information was col-
lected on healthcare utilization from randomization until maternal 
primary hospital discharge after birth and infant primary hospital dis-
charge home. Table 1 lists the 24 services and 11 hospital ward stays 
that were considered to assess cost.
The total maternal hospital length of stay was available, but not by 
hospital ward type, which varies substantially in cost; therefore, the 
operating room duration and labor and delivery ward duration before 
and after the actual birth time were estimated for each woman using 
the mean ward duration by parity and delivery mode observed from a 
trial of women who had an external cephalic version for breech pre-
sentation.5 Women who received magnesium sulfate before or during 
delivery had their postnatal labor and delivery ward duration estimate 
increased to 24 hours after delivery for monitoring purposes accord-
ing to Canadian guidelines. All women were assumed to have had a 
labor and delivery room duration, including those who went in to the 
operating room during which time their bed was held. Time in hospi-
tal after hospital admission (but before estimated labor and delivery 
ward admission) was ascribed to the antenatal ward, and time after 
estimated labor and delivery discharge to actual hospital discharge 
was ascribed to the postnatal ward, totaling the actual maternal hos-
pital length of stay.
Infants admitted to high-level neonatal care did not have their ac-
tual level of care indicated, given the variability in definition of in-
termediate and intensive care across hospitals. For costing purposes, 
cases of high-level neonatal care were categorized masked to treat-
ment allocation into level 3 or level 2 neonatal ward care. Level 3 
neonatal intensive care was attributed to babies with characteristics 
consistent with provincial admission guidelines and billing defini-
tions, as follows: birth at <32 weeks, birth weight <1500 g, receipt of 
any positive pressure ventilation (continuous positive airway pressure 
or endotracheal intubation), or any of ten serious neonatal morbidi-
ties (ie, patent ductus arteriosus, early-onset sepsis within the first 48 
hours of life, bronchopulmonary dysplasia, retinopathy of prematuri-
ty stage >2, intraventricular hemorrhage, cystic periventricular leuko-
malacia, hypoxic-ischemic encephalopathy, necrotizing enterocolitis, 
laparotomy, or thoracotomy). All other high-level neonatal care was 
regarded as level 2 intermediate care. Any neonatal hospital transfer 
was assumed to be for the purposes of the other type of care (ie, level 
3 transfer to level 2 and level 2 transfer to level 3).
Unit Costs for Physician Services and Wards
Physician services were costed using the provincial government 
health insurance plan schedule of medical benefits applicable to 2013 
for Ontario, British Columbia, and Alberta.6–8 Healthcare billing 
experts and clinicians in each province assisted with the identification 
and interpretation of appropriate billing codes. All services involved 
a flat fee or a time-dependent fee component, usually to a maximum 
amount, and a time of day and day of week premium (ie, for evening, 
night, and weekend calls). Accordingly, the fees for some services 
varied for each woman in the trial and were applied individually at 
the record level. An average unit cost per patient was calculated to 
generally illustrate the unit costs applied in each province (Table S1). 
Hospital ward durations were costed using unit costs by ward type 
and delivery mode determined for an economic analysis for a simi-
lar perinatal study in 2002, the TBT (Term Breech Trial),9 that were 
updated to 2013 using the Canadian Consumer Price Index healthcare 
commodity group of 20.5%.10 Ward unit costs were not province spe-
cific, but were derived in the TBT from reports from 4 teaching hos-
pitals and 3 community hospitals in each of the included provinces 
(ie, Ontario, British Columbia, and Alberta) combined into 1 median 
unit cost per ward type per hour (Table S2). Further definitions and 
assumptions for physician services and ward durations are included 
in Table S3. Table S4 summarizes the methods used to derive hospital 
ward unit costs and their application in this study.
Data Analysis
Costing involved multiplying the actual amount of resources con-
sumed by each participant as collected in the trial by their respec-
tive unit costs to determine the total cost of each of 24 services and 
each of 11 ward stays. The total cost of all 24 services, the total cost 
of all 11 wards, and the overall total cost of all services and wards 
were calculated using each province’s unit costs for less tight and 
tight BP management groups. All results were analyzed according 
to the intention-to-treat approach that included 493 women in the 
less tight group and 488 women in the tight group, and excluded 6 
women who withdrew or were lost to follow-up in CHIPS (Control 
of Hypertension in Pregnancy Study). The total per-participant costs 
for mothers and infants in each arm of the trial were not assumed 
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Table 1. Healthcare Resources Consumed by Study Groups in Trial
Healthcare Resource Consumed (24 Services and 11 Hospital Ward Lengths 
of Stay)










 1. Antenatal visit—Physician service 3683 483 3787 473
 2. Antepartum home care visit—Nursing service 545 108 529 105
 3. Obstetric day unit visit—Physician service 653 181 636 181
 4. Obstetric day unit visit—Ward care 653 visits (7836 h) 181 636 visits (7632 h) 181
 5. Emergency room visit—Physician service 403 199 387 177
 6. Emergency room visit—Ward care 403 (2015 h) 199 387 (1935 h) 177
Antenatal hospitalizations not for delivery
 7.  Antenatal hospital admission not for delivery, and daily  
care—Physician service
163 131 145 121
 8. Antenatal hospital admission not for delivery, length of stay—Ward care 450 days (10 800 h) 131 460 days (11 040 h) 121
Diagnostic tests
 9. Maternal blood and urine tests—Physician laboratory service 2433 459 2306 450
 10. Nonstress tests—Physician service 1878 359 2137 355
 11. Fetal ultrasounds—Physician service 1653 458 1631 454
 12. Infant chest x-rays—Physician service 277 74 163 54
 13. Infant head ultrasound—Physician service 166 68 118 62
 14. Infant head CT scan—Physician service 2 1 3 3
 15. Infant MRI—Physician service 5 4 3 3
 16. Ophthalmology examination for ROP—Physician service 97 66 84 59
Hospital length of stay for delivery
 17. Antenatal ward 30 584.76 h 480 29 573.31 h 474
 18. Labor and delivery ward 6559.24 h 493 6171.56 h 488
 19. Operating room 335.86 h 258 375.38 h 290
 20. Postnatal ward 39 263.77 h 493 37 061.70 h 488
Delivery
 21.  Caesarean section delivery before labor—Physician service 
(obstetrician, assistant, and anesthetist)
159 159 163 163
 22.  Caesarean section delivery during labor (CS and spontaneous or 
induced)—Physician service (obstetrician, assistant, and anesthetist)
72 72 87 87
 23. Spontaneous vaginal delivery—Physician service 234 234 196 196
 24. Operative vaginal delivery—Physician service 27 27 40 40
 25. Elective termination—Physician service 1 1 1 1
 26. Miscarriage—Physician service 0 0 1 1
 27. Induction—Physician service 224 224 218 218
Neonatal care
 28. NICU level 2 at delivery hospital—Physician service 765 d 84 664 d 83
 29. NICU level 3 at delivery hospital—Physician service 2531 d 72 1680 d 68
 30. NICU level 2 at transfer hospital—Physician service 580 d 19 424 d 15
 31. NICU level 3 at transfer hospital—Physician service 134 d 6 77 d 8
Aggregated: NICU level 2 and level 3 at both delivery and transfer hospital—
Physician service (Total high-level neonatal physician service)
96 240 h (4010 d) 156 68 280 h (2845 d) 151
(Continued )
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to be normally distributed. As such, the standard errors (SEs) of the 
difference in the means between groups and 95% CIs of the differ-
ences in the means were estimated using bootstrap methods and P 
values were estimated using permutation in “R” statistical software 
version 3.2.2.11 For each province, CIs and P values were estimated 
for all services, all wards, and for all services and all wards together. 
To demonstrate which specific services or wards were cost-drivers 
between less tight and tight control, we determined the absolute dif-
ference in mean cost between study groups for each service and ward, 
ranked the cost differences in descending order of magnitude, and for 
the top 5 cost-drivers where parameters were similarly estimated, we 
tested their significance assuming no distribution and using permuta-
tion, and found their 95% CIs using boot-strapping.
Results
Primary/transfer hospital ward durations were costed to a max-
imum of 305 days after which no women or babies remained 
in hospital. Women and infants in the less tight group relative 
to the tight group consumed less of 7 services and spent less 
time on 2 wards (antenatal physician visits, nonstress tests, 
antenatal hospitalization not for delivery ward time, Caesarean 
section delivery before labor, Caesarean section delivery dur-
ing labor, operative vaginal deliveries, miscarriages, operating 
room time, and infant head CT scans), but consumed more 
of 16 services and spent more time on 9 wards (antepartum 
home care visits with a nurse, obstetric day unit visits and ward 
time, emergency room visits and ward time, antenatal hospi-
tal admissions not for delivery, maternal blood and urine tests, 
fetal ultrasounds, infant chest x-rays, infant head ultrasounds 
and MRIs, ophthalmology exams for retinopathy of prema-
turity, longer lengths of stay in the antenatal ward, labor and 
delivery ward, postnatal ward, more spontaneous vaginal 
deliveries, inductions for labor, and more physician care and 
longer length of stay in level 2 and level 3 neonatal care at 
delivery and transfer hospitals). Both groups had the same 
number of elective terminations (Table 1). Although the less 
tight (compared with the tight) group had a similar number of 
overall admissions to high-level neonatal care level 2 or 3 (156 
versus 151 neonates), the total length of stay of less tight group 
neonates was substantially longer (total of 3921.34 days versus 
2763.96 days, or 41.8% more days), especially in level 3 neo-
natal intensive care at delivery hospitals, an important differ-
ence with associated clinical implications, regardless of cost.
The mean cost in each group represents the total cost 
incurred for each service or ward consumed by women in that 
group divided by the total number of women (493 or 488) in 
the study group, whether or not they incurred the service or 
ward (Table S5). Overall, there was no significant difference 
in the mean cost of all services and wards between less tight 
and tight control groups in each province (Table 2), with simi-
lar direction and magnitude of effect. Women in the less tight 
control group incurred costs that were close to $6000 dollars 
more than women in the tight control, but the difference was 
not statistically significant.
Table S6 shows the top 5 items with the greatest difference 
in mean cost between the study groups. All were related to 
 32. NICU level 2—Delivery hospital—ward care 724.28 d 84 626.09 d 83
 33. NICU level 3—Delivery hospital—ward care 2495.32 d 72 1651.02 d 68
 34. NICU level 2—Transfer hospital—ward care 570.44 d 19 414.39 d 15
 35. NICU level 3—Transfer hospital—ward care 131.29 d 6 72.46 d 8
Aggregated: NICU level 2 and level 3 at both delivery and transfer hospital 
(Total high-level neonatal ward care)
94 112.04 h  
(3921.34 d)
156 66 334.68 h  
(2763.95 d)
151
CS indicates Caesarean section; CT, computed tomography; MRI, magnetic resonance imaging; NICU, neonatal intensive care unit; and ROP, retinopathy of prematurity.
Table 1. Continued
Healthcare Resource Consumed (24 Services and 11 Hospital Ward Lengths 
of Stay)























in Means) P ValueMean SE (Mean) Mean SE (Mean)
Total cost of 
all services 
and wards
Ontario $30 191.62 $2703.18 $24 469.06 $1646.23 $5723 −$296, $12 272 $3184.89 0.0725
B.C. $30 593.69 $2756.47 $24 776.51 $1668.60 $5817 −$385, $12 349 $3227.88 0.0725
Alberta $31 510.72 $2821.73 $25 510.49 $1705.26 $6000 −$154, $12 781 $3308.47 0.0637
Total cost of 
all services
Ontario $3323.27 $137.19 $3060.41 $105.75 $263 −$62, $606 $170.74 0.1351
B.C. $3725.34 $187.12 $3367.85 $128.02 $357 −$80, $826 $230.30 0.1197
Alberta $4642.37 $255.44 $4101.83 $168.68 $541 −$42, $1170 $305.50 0.0784
Total cost of 
all wards
All Provinces $26 868.35 $2573.40 $21 408.65 $1546.70 $5460 −$202, $11 560 $3015.76 0.0694
SE indicates standard error. *Positive value favors less costly tight group.
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neonatal intensive care. The top 4 cost-drivers were neonatal 
care ward costs at the delivering and transfer hospitals. In the 
less tight group, high-level neonatal intensive care ward costs 
represented the majority of overall costs: at 56.8% of over-
all cost per woman/infant dyad in Ontario, 56.1% in British 
Columbia, and 54.5% in Alberta. There was no statistically 
significant difference between the study groups in any of the 
top 5 cost drivers.
Discussion
Main Findings
There has been much debate about the best approach to the 
management of hypertension.2 The CHIPS trial showed that 
tight BP control is not harmful to the baby, and consistent 
with literature from other clinical trials, was beneficial to the 
mother by decreasing the development of severe hyperten-
sion.12 To our knowledge, the analysis reported here is the 
first to compare the cost implications of less tight versus tight 
BP control strategies for pregnancy hypertension. The study 
found that the mean cost per woman–infant dyad managed 
by a policy of less tight (versus tight) BP control is not sig-
nificantly different with regard to overall services and hospital 
ward costs incurred from as early as from 14 weeks of gesta-
tion up to 305 days after delivery (ie, last neonatal primary 
hospital discharge date recorded), using costs obtained from 
Ontario, British Columbia, or Alberta, Canada.
Although costs in each province were almost $6000 
higher for the less tight group in which infants spent more 
time in high-level neonatal intensive care wards, the result did 
not reach statistical significance and may reflect a lack of sta-
tistical power.13,14
The upper and lower limits of the 95% CI can be examined 
to determine whether they would exclude a minimally impor-
tant (cost) difference (MID), like that used for noninferiority 
trials.15,16 If the MID is either outside or included within both 
CI boundaries, then neither treatment strategy is significantly 
different in cost and the decision threshold to change policy 
is not reached. However, if an MID is included on one side 
of the 95% CI boundaries but not on the other, the decision 
threshold is reached for that treatment if adopted, and would 
be associated with cost savings per patient to at least the level 
of the MID: similar savings would not be experienced if the 
alternate treatment approach was adopted. In our study, a deci-
sion maker might determine, for example, that a difference 
in mean cost per patient of ±$500 is an MID threshold above 
which a less tight or tight policy would be attractive to imple-
ment. Using outcomes for British Columbia in our study, the 
total mean cost per patient was $30 593.69 for less tight and 
$24 776.51 for tight groups, with a difference in mean costs 
of $5817, and CI of −$385 cost savings up to a $12 349 cost 
increase, for a less tight patient (Table 2). In this example, with 
an MID of $500, we could exclude a cost savings with a policy 
of less tight control. Tight control may be substantially cheaper 
with a marked reduction in neonatal intensive care unit days.
Study Strengths and Limitations
The data come from CHIPS, a large, international, multi-
center randomized trial. Resource utilization was measured 
prospectively and the economic analysis planned, all con-
tributing to minimization of bias in cost assessment between 
groups. The analysis used mean costs from 3 Canadian 
provinces with different fee structures related to provin-
cial schedules of medical benefits, especially flat rate fees, 
premiums for start time of day and day of week, and time-
dependent fees. The direction and magnitude in the differ-
ence in mean cost of overall services and wards in each of 
the 3 provinces were similar, all favoring tight control as less 
expensive. The purpose of conducting the analysis in each 
province was to demonstrate the independence of findings 
from the effect of jurisdiction and price structures, similar to 
a sensitivity analysis. Any specific cost differences between 
provinces are ultimately less important than the fact that the 
interventions were costed in 3 different healthcare jurisdic-
tions with different funding and price structures, yet pro-
duced a similar magnitude and direction in results, which 
supports the validity of the findings. There were no major 
differences between provinces, which supports the general-
izability in this context.
Our study is limited by the application of 2002 TBT 
ward unit costs scaled for health commodity inflation in 
Canada to 2013 trial data: true ward unit costs incurred by 
hospitals in each province in 2013 may be different. The 
TBT combined ward type unit cost data for each province, 
so we could not report province-specific total ward costs. 
TBT ward unit costs were derived for women with breech 
pregnancies, their infants and costs of related complica-
tions, which may underestimate these costs for hyperten-
sive pregnancies. However, hypertension-specific care was 
accounted for, such as more time allocated on the labor and 
delivery ward to women on magnesium sulfate to capture 
the enhanced nursing care required. CHIPS women may 
have had different mean lengths of stay on the labor and 
delivery ward and in the operating room for Caesareans 
than those in the EECV2 (Early External Cephalic Version 
2) trial from which costs were estimated, although these 
durations are not likely to be substantially different in the 
overall findings, and total hospital length of stay in CHIPS 
was preserved. Whereas CHIPS women may have received 
more interventions than EECV2 women, this approach is 
conservative and has been applied equally to both the study 
groups. The neonatal intensive care level 3 ward unit cost of 
$107.00/h from the TBT may be higher for CHIPS neonates 
who may require a higher intensity of hospital care, related 
to nursing staff time, hospital service consumables used, 
and associated ward costs. The time spent in any high-level 
care was preserved, but we were unable to standardize a def-
inition of levels 2 and 3 neonatal care across jurisdictions: 
categorization of high-level neonatal care into levels 2 and 
3 care cases was performed according to an algorithm that 
may not have reflected the true level, intensity and cost of 
care received. Although every attempt was made to ensure 
the correct billing codes in each province were applied to 
the physician service resources consumed in CHIPS, actual 
billing practice of individual physicians vary by individual 
practice (such as the use of after-hours codes), time of day, 
and day of week that care was provided. The trial collected 
data from 94 centers in 15 countries, with centers selected 
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to have similar facilities, conditions and medical practices 
to fulfill the CHIPS Protocol as in Canada. However, the 
resources consumed in the trial may differ from that which 
would have been consumed in the actual Canadian context, 
although any potential differences cannot be easily ascer-
tained. Nonetheless, the application of any estimates was 
applied to both groups equally. As for all clinical efficacy sce-
narios, our results apply to the 3 provinces mentioned because 
we used their unit prices. No subgroup analysis was done with 
Canadian study participants only.
The CHIPS trial, as with many randomized controlled 
trials, was powered for the primary study outcome and not 
the cost analysis, which typically requires larger sample sizes 
because of large variances and positively skewed distributions 
of cost, as observed in this analysis. It is possible that a larger 
sample size may have confirmed the observed trend toward a 
higher mean cost per woman in the less tight group, driven by 
the longer infant length of stay in high-level neonatal intensive 
care units. More than 55% of the cost of care was attributed 
to neonatal costs, which was the top cost-driver in each of the 
3 provinces, raising the possibility that differences seen in the 
primary study may be real.
Perspectives
The mean cost for women/infants under a less tight treatment 
approach to pregnancy hypertension is not different to those 
under a tight control approach. However, based on our find-
ings, there is little chance that less tight control is cheaper; 
and in the main CHIPS Study, less tight control was impli-
cated in significantly more morbidity among women. Thus, a 
treatment approach of tight control of pregnancy hypertension 
may have clinical benefit for women, with no increased risk to 
neonates and without additional (and possibly lower) cost to 
the healthcare system.
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What Is New?
•	This study presents a cost analysis of less tight versus tight blood pres-
sure management strategies for women with chronic or gestational hy-
pertension in a large, multicenter randomized controlled trial.
What Is Relevant?
•	The CHIPS trial (Control of Hypertension in Pregnancy Study) found no 
difference in pregnancy loss or high-level neonatal care >48 hours when 
comparing a less tight (target 100 mm Hg) and tight (target 85 mm Hg) 
approach to blood pressure management during pregnancy. However, 
women in the CHIPS study experienced significantly less morbidity with 
a tight approach.
•	No significant difference was found in mean total cost of all services and 
wards per woman–infant dyad between less tight versus tight strategies.
Summary
Tight blood pressure control in pregnancy may benefit women 
without increasing risk to neonates (as shown in the main CHIPS 
trial), without additional (and possibly lower) cost to the healthcare 
system.
Novelty and Significance
